Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

RCT (n=853) found that secukinumab was not superior to adalimumab for ACR20 response (67% vs 62% respectively, p=0.0719), though the retention rate at 1 year was superior for secukinumab (14% vs 24% had discontinued treatment by the end of the study respectively.

SPS commentary:

A related commentary discusses this research, stating that this trial undoubtedly provides important new knowledge regarding the comparative efficacy and safety of two biological drugs with different mechanisms of action.


The Lancet

Resource links: